S&P 500   5,119.92 (-1.52%)
DOW   37,944.12 (-1.34%)
QQQ   437.24 (-1.83%)
AAPL   175.34 (+0.17%)
MSFT   420.21 (-1.80%)
META   511.18 (-2.29%)
GOOGL   157.26 (-1.35%)
AMZN   185.36 (-1.95%)
TSLA   170.56 (-2.31%)
NVDA   885.55 (-2.27%)
AMD   162.87 (-4.48%)
NIO   4.11 (-7.85%)
BABA   71.88 (-3.97%)
T   16.32 (-0.61%)
F   12.55 (-3.76%)
MU   122.90 (-3.62%)
GE   154.15 (-2.06%)
CGC   7.92 (-2.82%)
DIS   114.07 (-2.63%)
AMC   2.67 (-4.64%)
PFE   25.90 (-1.67%)
PYPL   64.34 (-2.22%)
XOM   120.98 (-0.67%)
S&P 500   5,119.92 (-1.52%)
DOW   37,944.12 (-1.34%)
QQQ   437.24 (-1.83%)
AAPL   175.34 (+0.17%)
MSFT   420.21 (-1.80%)
META   511.18 (-2.29%)
GOOGL   157.26 (-1.35%)
AMZN   185.36 (-1.95%)
TSLA   170.56 (-2.31%)
NVDA   885.55 (-2.27%)
AMD   162.87 (-4.48%)
NIO   4.11 (-7.85%)
BABA   71.88 (-3.97%)
T   16.32 (-0.61%)
F   12.55 (-3.76%)
MU   122.90 (-3.62%)
GE   154.15 (-2.06%)
CGC   7.92 (-2.82%)
DIS   114.07 (-2.63%)
AMC   2.67 (-4.64%)
PFE   25.90 (-1.67%)
PYPL   64.34 (-2.22%)
XOM   120.98 (-0.67%)
S&P 500   5,119.92 (-1.52%)
DOW   37,944.12 (-1.34%)
QQQ   437.24 (-1.83%)
AAPL   175.34 (+0.17%)
MSFT   420.21 (-1.80%)
META   511.18 (-2.29%)
GOOGL   157.26 (-1.35%)
AMZN   185.36 (-1.95%)
TSLA   170.56 (-2.31%)
NVDA   885.55 (-2.27%)
AMD   162.87 (-4.48%)
NIO   4.11 (-7.85%)
BABA   71.88 (-3.97%)
T   16.32 (-0.61%)
F   12.55 (-3.76%)
MU   122.90 (-3.62%)
GE   154.15 (-2.06%)
CGC   7.92 (-2.82%)
DIS   114.07 (-2.63%)
AMC   2.67 (-4.64%)
PFE   25.90 (-1.67%)
PYPL   64.34 (-2.22%)
XOM   120.98 (-0.67%)
S&P 500   5,119.92 (-1.52%)
DOW   37,944.12 (-1.34%)
QQQ   437.24 (-1.83%)
AAPL   175.34 (+0.17%)
MSFT   420.21 (-1.80%)
META   511.18 (-2.29%)
GOOGL   157.26 (-1.35%)
AMZN   185.36 (-1.95%)
TSLA   170.56 (-2.31%)
NVDA   885.55 (-2.27%)
AMD   162.87 (-4.48%)
NIO   4.11 (-7.85%)
BABA   71.88 (-3.97%)
T   16.32 (-0.61%)
F   12.55 (-3.76%)
MU   122.90 (-3.62%)
GE   154.15 (-2.06%)
CGC   7.92 (-2.82%)
DIS   114.07 (-2.63%)
AMC   2.67 (-4.64%)
PFE   25.90 (-1.67%)
PYPL   64.34 (-2.22%)
XOM   120.98 (-0.67%)
NASDAQ:XBIO

Xenetic Biosciences (XBIO) Stock Price, News & Analysis

$4.33
-0.10 (-2.26%)
(As of 10:50 AM ET)
Today's Range
$4.33
$4.46
50-Day Range
$3.56
$4.72
52-Week Range
$2.55
$5.97
Volume
1,301 shs
Average Volume
6,046 shs
Market Capitalization
$6.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Xenetic Biosciences MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Xenetic Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.43) to ($0.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.96 out of 5 stars

XBIO stock logo

About Xenetic Biosciences Stock (NASDAQ:XBIO)

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

XBIO Stock Price History

XBIO Stock News Headlines

Xenetic Biosciences Inc (XBIO)
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Xenetic Dips on Full-Year Results
Xenetic Biosciences reports FY results
Xenetic Biosciences Inc XBIO
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Xenetic Biosciences: Q3 Earnings Insights
MediciNova: Q3 Earnings Snapshot
XBIO Xenetic Biosciences, Inc.
XBIO.PH - | Stock Price & Latest News | Reuters
See More Headlines
Receive XBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
4/12/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:XBIO
Fax
N/A
Employees
4
Year Founded
2011

Profitability

Net Income
$-4,140,000.00
Net Margins
-162.84%
Pretax Margin
-162.79%

Debt

Sales & Book Value

Annual Sales
$2.54 million
Book Value
$6.36 per share

Miscellaneous

Free Float
1,402,000
Market Cap
$6.67 million
Optionable
Not Optionable
Beta
2.60

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Jeffrey F. Eisenberg (Age 53)
    CEO & Director
  • Mr. James F. Parslow (Age 54)
    CFO, COO & Corp. Sec.
  • Dr. Curtis A. Lockshin (Age 59)
    Chief Scientific Officer

XBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Xenetic Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" XBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XBIO, but not buy additional shares or sell existing shares.
View XBIO analyst ratings
or view top-rated stocks.

How have XBIO shares performed in 2024?

Xenetic Biosciences' stock was trading at $3.45 at the start of the year. Since then, XBIO shares have increased by 25.5% and is now trading at $4.33.
View the best growth stocks for 2024 here
.

Are investors shorting Xenetic Biosciences?

Xenetic Biosciences saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 1,700 shares, a decrease of 22.7% from the March 15th total of 2,200 shares. Based on an average daily trading volume, of 6,100 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.1% of the company's shares are short sold.
View Xenetic Biosciences' Short Interest
.

When is Xenetic Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our XBIO earnings forecast
.

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) issued its quarterly earnings data on Thursday, November, 11th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $0.10. The company earned $0.35 million during the quarter, compared to the consensus estimate of $0.20 million. Xenetic Biosciences had a negative trailing twelve-month return on equity of 36.43% and a negative net margin of 162.84%.

When did Xenetic Biosciences' stock split?

Xenetic Biosciences shares reverse split on Monday, May 15th 2023. The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX).

How do I buy shares of Xenetic Biosciences?

Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XBIO) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners